Kyorin Pharmaceutical has discovered and developed Imidafenacin.
Kyorin Pharmaceutical grants Daiichi Sankyo rights to activities related to the development and marketing of Imidafenacin in Brazil, as per the agreement.
Imidafenacin is a anticholinergic agent that acts as a selective antagonist on M3 and M1 muscarinic subtype receptors to improve the urgency of urination, pollakiuria and urge urinary incontinence associated with OAB.